Star Combo Pharma Ltd Capital Reinvestment Ratio
Star Combo Pharma Ltd capital reinvestment ratio. Star Combo Pharma Ltd (S66) has a Capital Reinvestment Ratio of 0.51x as of December 2025, meaning it reinvests 1% of its operating cash flow (AU$575.23K) in capital expenditures (AU$295.53K). See S66 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Star Combo Pharma Ltd (2016–2025)
Capital reinvestment ratio of Star Combo Pharma Ltd from 2016 to 2025. This chart tracks Star Combo Pharma Ltd's Capital Reinvestment Ratio across 6 annual periods. See S66 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Star Combo Pharma Ltd Capital Reinvestment Ratio by Year (2016–2025)
Star Combo Pharma Ltd capital reinvestment ratio by year from 2016 to 2025. For the full cash flow conversion analysis, see Star Combo Pharma Ltd operating cash flow efficiency.
| Year | Reinvestment Ratio | Operating CF (AUD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.03x | AU$11.94 Million | AU$393.72K | ▼ -97.7% |
| 2023 | 1.45x | AU$1.88 Million | AU$2.73 Million | ▼ -98.3% |
| 2022 | 83.74x | AU$87.11K | AU$7.29 Million | ▲ +282.5% |
| 2021 | 21.89x | AU$331.53K | AU$7.26 Million | ▲ +7714.6% |
| 2017 | 0.28x | AU$932.20K | AU$261.13K | ▼ -68.3% |
| 2016 | 0.88x | AU$1.30 Million | AU$1.15 Million | — |